Corporate News
LR Health & Beauty SE publishes figures for the first half of 2025 and adjusts its forecast for 2025
LR Health & Beauty SE publishes figures for the first half of 2025 and adjusts its forecast for 2025
- EUR 142.9 million in sales achieved in the first half of 2025
- EBITDA reported improved by 13.6% to EUR 13.3 million
- Newly appointed management team with CEO Jörg Körfer and Interim CFO Ante Franicevic drives further development of corporate strategy
- Planned discussions with bondholders of the 2024/2028 bond regarding a precautionary resolution on a waiver of compliance with the Leverage Covenant as at 30 September 2025 and an amendment to the bond terms
- Sales and earnings guidance for financial year 2025 adjusted
Ahlen, 28 August 2025 – LR Health & Beauty SE, Europe’s leading digital social commerce company for high-quality nutritional supplements and beauty products, today published its results for the second quarter and the first half of 2025. In the second quarter of the financial year 2025, LR Health & Beauty SE generated sales (revenue from goods sold) of EUR 68.9 million (Q2 2024: EUR 70.7 million) – a decline of 2.6%. In the first half of the year, sales amounted to EUR 142.9 million, representing a slight decrease of 0.3% compared with the prior-year figure of EUR 143.3 million. This development reflects the generally subdued consumer sentiment, particularly noticeable in Western European markets.
In addition, LR Health & Beauty SE achieved EBITDA reported of EUR 13.3 million in the first six months of 2025, representing a significant increase of 13.6% compared with the prior-year period (H1 2024: EUR 11.7 million). In the prior-year period, refinancing costs incurred in connection with the redemption of the previous bond had weighed on earnings. Normalized EBITDA increased by 6.3% to EUR 15.3 million in the first half of 2025 (H1 2024: EUR 14.4 million).
Valdemaras Gordinskis, Vice President Global Controlling and Investor Relations LR Health & Beauty SE, comments: “In the first half of 2025, we focused on further enhancing the foundations for the business success of our distributors. Our product innovations play an important role in this. Through regular product launches and the targeted expansion of our portfolio, we are opening up attractive business opportunities for our distributors in a generally challenging market environment.”
New leadership team with proven expertise
With a newly formed leadership team, LR is consistently driving the further development of its corporate strategy. As of 1 August 2025, Mr Jörg Körfer was appointed Chief Executive Officer (CEO). He brings extensive expertise in global direct sales from his many years of senior management positions at internationally operating companies, including Bofrost and Vorwerk. In addition, LR has strengthened its management team with the appointment of Mr Ante Franicevic, who serves as Interim Chief Financial Officer (CFO). Mr Franicevic contributes more than 20 years of senior management experience in finance at well-known retail and consumer brands such as Douglas, Jack Wolfskin and Metro.
Jörg Körfer, CEO of LR Health & Beauty SE, states: “As a newly formed leadership team, our clear goal is to continue LR’s success story as Europe’s leading social commerce company. Our Global Leader Convention in Berlin, marking the company’s 40th anniversary, and the Business Days in September provide an ideal opportunity to strengthen our engagement with our community members and to launch new business initiatives. Together with our distributors, we aim to make the company even stronger and more innovative, thereby ensuring sustainable success for LR in a challenging market environment.”
2024/2028 bond
Today, the Management Board of LR Health & Beauty SE resolved to initiate precautionary negotiations with the holders of the 2024/2028 bond (ISIN: NO0013149658) regarding a proposal to amend the bond terms and, if necessary, to request their consent to a waiver of the Leverage Covenant as at 30 September 2025. The background is a potential breach of the company’s obligation under Clause 13.2 of the bond terms, which requires the company to ensure that net debt in relation to EBITDA (the “Leverage Covenant”) does not exceed the threshold of 4.50:1 as at 30 September 2025. The Leverage Covenant was reduced from 4.75:1 to 4.50:1 as of 1 July 2025. Based on preliminary calculations, the Management Board currently assumes that the Leverage Covenant is unlikely to be met on the review date of 30 September 2025. This is due to EBITDA developing less favourably than expected, primarily due to increased or increasing costs in the areas of marketing and sales.
Outlook 2025
Furthermore, LR’s Management Board is adjusting the guidance for the 2025 financial year published on 25 April 2025. With regard to sales (revenue from goods sold), the Management Board now expects a stable development compared with the previous year. Previously, stable to moderately increasing sales had been forecast. EBITDA for the 2025 financial year is now expected to range between EUR 24.0 million and EUR 27.0 million – whereas the previous guidance anticipated significant EBITDA growth compared to the previous year’s figure of EUR 27.3 million. The revision of the EBITDA guidance is essentially due to increased or increasing costs in the areas of marketing and sales. This trend also continued in July, leading the Management Board to conclude that the previous guidance is unlikely to be achieved through catch-up effects or cost-saving measures.
The full report for the second quarter and the first half of 2025 will be available from 29 August 2025 on the corporate website: https://ir.lrworld.com/.
LR Group
Under the motto “More quality for your life”, the LR Group – headquartered in the town of Ahlen/Westphalia – successfully produces and distributes various high-quality nutritional supplements and cosmetic products in 32 countries. As an attractive Social Commerce Company, LR supports the personal exchange in its community with efficient, digital solutions. The holistic tool “LR neo” offers the international partnership all business-relevant key figures and information for their LR business in one dashboard.
Since 1985, LR has been firmly established in the market as a “people business” with a focus on people and personal consultation. In times of changing working environments, the business model is particularly appealing to those who are looking for more flexibility, a better work-life balance and greater financial independence.
The processing of aloe vera has been one of LR’s core competencies for over 20 years. Only the leaf’s valuable inside is used for the products. In Ahlen, the company has built one of the most modern aloe vera production facilities for aloe vera drinking gels in Europe.
In the fall of 2009, LR founded the LR Global Kids Fund e.V., which supports disadvantaged children and their families in many countries around the world efficiently and without the usual red tape in cooperation with local institutions. For further information on our commitment to sustainability, please read our Sustainability Report.
LR currently has around 1,200 employees and hundreds of thousands of registered community members.
Contact:
PR contact:
LR Health & Beauty SE
Almut Kellermeyer
Head of Corporate Communication
Kruppstraße 55
59227 Ahlen
Phone: +49(0)2382 7658-106
E-mail: a.kellermeyer@LRworld.com
https://ir.lrworld.com/
IR contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de
LR Health & Beauty welcomes Jörg Körfer as new CEO – focus remains on growth and operational excellence
LR Health & Beauty welcomes Jörg Körfer as new CEO – focus remains on growth and operational excellence
Ahlen, 21 July 2025 – LR Health & Beauty SE announces that Mr Jörg Körfer has been appointed Chief Executive Officer (CEO). He will take over the responsibilities of the previous members of the Management Board, Dr Andreas Laabs and Andreas Grootz, with effect from 1 August 2025. Both gentlemen will leave the company by mutual agreement on 31 July 2025. In order to further strengthen the management team in the future, the Supervisory Board is exploring options for another complementary member of the Management Board.
Jörg Körfer has extensive expertise in global direct sales from his many years of management experience with international companies. Among other things, he spent 14 years at Vorwerk (CEO Kobold and CEO Thermomix) and served as Chairman of the Advisory Board at Bofrost for six years, as well as acting as CEO in an advisory capacity. He will now bring this experience to LR and continue to exploit the full potential of Europe’s leading social commerce platform in line with the strategy that has been pursued.
The Supervisory Board would like to express its sincere thanks to the two departing members of the Management Board for their trust and dedication. Under Dr Laabs’ leadership in particular, LR has developed excellently over the past eleven years and is ideally positioned to enter its next phase of growth. Since joining LR in 2014, Dr Laabs has played a key role in shaping the company and successfully transformed LR from a traditional direct sales model into a globally active social commerce company. The key milestones of his tenure include the digitalisation of the business model, several of LR’s most successful product launches, and infrastructure projects such as the insourcing of Aloe Vera Drinking Gels in 2018 and the opening of the IT hub in Athens, all of which have contributed significantly to LR’s current position.
Andreas Grootz is leaving the company after fourteen years. He established capital market-compatible governance structures at LR and drove forward the opening of new markets.
The Supervisory Board is confident that Mr Körfer is the right successor to LR to continue the success story started by Dr Laabs and his team.
Contact:
Public Relations:
LR Global Holding
Almut Kellermeyer
Head of PR / Public Affairs
Kruppstraße 55
59227 Ahlen
Tel.: +49(0)2382 7813-106
Email: a.kellermeyer@LRworld.com
https://ir.lrworld.com/
Investor Relations:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Building D
65195 Wiesbaden
Tel.: +49(0)611 – 205855-23
Fax: +49(0)611 – 205855-66
Email: burbach@cometis.de
LR Health & Beauty SE grows profitably in the first quarter 2025
LR Health & Beauty SE grows profitably in the first quarter 2025
- Sales increased by 2.0% to EUR 74.0 million in the first quarter
- EBITDA reported significantly improved by 20.5% to EUR 7.4 million
- Digitalisation and process optimisation in logistics & IT increase efficiency
- Forecast for the financial year 2025 confirmed
Ahlen, 26 May 2025 – LR Health & Beauty SE, Europe’s leading digital social commerce company for high-quality nutritional supplements and beauty products, today published its figures for the first quarter of 2025. In the first three months of the financial year 2025, LR Health & Beauty SE generated sales (revenue from goods sold) of EUR 74.0 million (Q1 2024: EUR 72.6 million). Despite the generally subdued consumer sentiment in Europe, the company was able to increase sales by 2.0% compared to the first quarter of the previous year.
Furthermore, EBITDA reported amounted to EUR 7.4 million (Q1 2024: EUR 6.1 million) in the first quarter of 2025, which corresponds to a significant increase of 20.5% compared to the same period of the previous year. On the one hand, both the sales growth achieved, and overall stable cost structures had a positive effect. On the other hand, one-off extraordinary effects due to the premature refinancing of the old bond burdened the EBITDA reported in the previous year’s quarter. In the first quarter of 2025, normalized EBITDA rose by 4.9% to EUR 8.2 million compared to the corresponding value of the previous year of EUR 7.8 million.
Valdemaras Gordinskis, Vice President Global Controlling and Investor Relations of LR Health & Beauty SE, comments: “The good start to the 2025 financial year has confirmed that we have set the course for profitable growth with our strategic growth initiatives such as the realignment of the career plan and the continuous expansion of our product range.
With the ongoing digitalisation of our business processes and the launch of our new logistics centre, we are also successfully working towards making our business even more efficient and profitable.”
Successful digitalisation of business processes
The logistics centre at the Ahlen site has been fully commissioned and now also enables direct deliveries to LR sales partners and customers in various markets. At the heart of the logistics centre is a state-of-the-art storage system that increases efficiency and improves scaling possibilities. The further digitalisation of business processes is reflected not only in the optimised logistics, but also in the expansion of the company's own IT infrastructure. The opening of the IT hub in Athens is helping to ensure that business applications can increasingly be developed and operated internally.
Dr. Andreas Laabs, CEO of LR Health & Beauty SE summarises: “Our partner community has started the new year with a lot of energy, and we have seen a great response to our Business Days. With the launch of the new LR Aloe Via Magic Power Duo skincare range, we have furthermore underpinned our high quality standards in the field of skincare. We aim to utilise the tailwind from the first quarter to continue our growth trajectory. On top of seasonal sales initiatives such as ‘Crazy Summer’, we are also planning a major new product launch for the second half of the year, which will give our partner community further impetus for sales."
Outlook 2025
LR Health & Beauty still expects to be able to consistently utilize the growth opportunities in the Health & Beauty segments despite the tense market situation in large parts of Europe. Based on conservative assumptions, the company continues to expect stable to moderately rising sales (revenue from goods sold) and significantly higher EBITDA for the 2025 financial year compared to the previous year.
The full report for the first quarter is available from today on the company website at https://ir.lrworld.com/.
In addition, the Sustainability Report 2024 is now available for download at https://ir.lrworld.com/en/sustainability/.
LR Group
Following the motto "More quality for your life" the LR Group with headquarters in Ahlen/Westphalia successfully produces and markets various high-quality nutritional supplements and cosmetic products in 32 countries. As an attractive social commerce company, LR supports the personal exchange in its community with efficient, digital solutions. The holistic tool "LR neo" offers the international partnership all business-relevant key figures and information for their LR business in one dashboard.
LR has been firmly established on the market since 1985 as a "people business" company that focuses on people and personal advice. In times of changing working environments, the business model particularly appeals to those who are looking for more flexibility, a better work-life balance and greater financial independence.
The processing of Aloe Vera has been one of the core competencies of LR for more than 20 years. Only the valuable inside of the leaf is used for the products. In Ahlen, the company has established one of the most modern Aloe Vera production sites for Aloe Vera Drinking Gels in Europe.
In autumn 2009, LR founded the LR Global Kids Fund e.V., which supports deprived children and their families in many countries around the world efficiently and unbureaucratically in cooperation with local institutions. For further information on our commitment to sustainability, please read our sustainability report.
LR currently has around 1,200 employees and hundreds of thousands of registered community members.
Your Contacts:
PR Contact:
LR Health & Beauty SE
Almut Kellermeyer
Head of Corporate Communication
Kruppstraße 55
59227 Ahlen
Phone: +49(0)2382 7813-106
E-Mail: a.kellermeyer@LRworld.com
https://ir.lrworld.com/
IR Contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-Mail: burbach@cometis.de
Ad-hoc Announcements
LR GLOBAL HOLDING GMBH GIVES NOTICE OF CONDITIONAL VOLUNTARY TOTAL REDEMPTION OF ITS OUTSTANDING 2021/2025 BONDS AND LR HEALTH & BEAUTY SE ISSUES NEW SENIOR SECURED BONDS OF EUR 130 MILLION
NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, CYPRUS, HONG KONG, ITALY, JAPAN, NEW ZEALAND, SOUTH AFRICA, THE UNITED KINGDOM OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ANY FURTHER MEASURES FROM LR GLOBAL HOLDING GMBH, LR HEALTH & BEAUTY SE, PARETO SECURITIES AS, FRANKFURT BRANCH, ARCTIC SECURITIES AS OR ANY OTHER PARTY.
Disclosure of an inside information acc. to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)
LR GLOBAL HOLDING GMBH GIVES NOTICE OF CONDITIONAL VOLUNTARY TOTAL REDEMPTION OF ITS OUTSTANDING 2021/2025 BONDS AND LR HEALTH & BEAUTY SE ISSUES NEW SENIOR SECURED BONDS OF EUR 130 MILLION
Ahlen, 19 February 2024 – LR Global Holding GmbH (the “Company”) gives conditional notice of voluntary total redemption of its outstanding EUR 125 million senior secured 2021/2025 bonds with ISIN NO0010894850 (the “Existing Bonds”) in full and announces that the Company’s parent company LR Health & Beauty SE has, following a successfull book building process, placed new senior secured bonds with ISIN NO0013149658 due in 2028 with a nominal amount of EUR 130 million (the ”New Bonds”) and generating proceeds of approximately EUR 125 million.
A notice of a conditional voluntary total redemption of the Existing Bonds will be sent to Verdipapirsentralen ASA (Euronext Securities Oslo) (“VPS”) for delivery to persons registered in the securities account with VPS as holders of Existing Bonds.
The redemption is conditional upon successful settlement of the New Bonds and the receipt of the proceeds from the New Bonds by the Company from a designated escrow account prior to the lapse of 7 March 2024 (the “Condition”). Should the Condition not be fulfilled by the lapse of 7 March 2024, the redemption will not occur (unless the Condition has been waived by the Company at its sole discretion) which will, in such case, be communicated by the Company through a subsequent announcement.
Subject to the fulfilment or waiver of the Condition, the date for redemption is set at 11 March 2024 and the record date for the redemption will be 7 March 2024, i.e. two business days prior to the redemption date. The Existing Bonds will then be redeemed at an amount equal to 101.45 % of the total outstanding nominal amount (i.e., EUR 1,014.50 per Existing Bond) together with any unpaid interest accrued until but excluding the redemption date.
In connection with the redemption, the Existing Bonds will be delisted from Frankfurt Stock Exchange and Nasdaq Stockholm.
The New Bonds will have a term of 4 years and will carry a floating rate coupon of 3 months EURIBOR plus 7.5 % per annum. The Company intends to apply for admission to trading of the Bonds on the Open Market of the Frankfurt Stock Exchange and the corporate bond list of Nasdaq Stockholm.
This announcement is for information purposes only and is not to be construed as an offer to purchase or sell or a solicitation of an offer to purchase or sell with respect to any securities of the Company or LR Health & Beauty SE.
IR contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de
This information is information that LR Global Holding GmbH is obliged to make public pursuant to the EU Market Abuse Regulation (EU 596/2014). The information in this publication has been made public through the agency of the responsible person set out above for publication at the time stated by the Company's news distributor, EQS Group AG, at the time of publication.
Important Note
THE SECURITIES MENTIONED HEREIN HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE US SECURITIES ACT. THEY MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT. NO PUBLIC OFFERING WILL BE MADE IN THE UNITED STATES AND THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFER TO SELL NOR A SOLICITATION TO BUY OR SUBSCRIBE FOR SECURITIES OF LR GLOBAL HOLDING GMBH AND/OR LR HEALTH & BEAUTY SE AND NO EXCHANGE OFFER IS BEING MADE IN THE UNITED STATES, AUSTRALIA, CANADA, CYPRUS, HONG KONG, ITALY, JAPAN, NEW ZEALAND, SOUTH AFRICA, THE UNITED KINGDOM OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION/SUCH OFFER WOULD REQUIRE ANY FURTHER MEASURES FROM LR GLOBAL HOLDING GMBH, LR HEALTH & BEAUTY SE, PARETO SECURITIES AS, FRANKFURT BRANCH, ARCTIC SECURITIES AS OR ANY OTHER PARTY OR BE PROHIBITED BY APPLICABLE LAW.
LR GLOBAL HOLDING GMBH ANNOUNCES ITS INTENTION TO EXERCISE THE CALL-OPTION TO REDEEM ITS OUTSTANDING 2021/2025 BONDS SUBJECT TO A SENIOR SECURED BOND ISSUANCE BY LR HEALTH & BEAUTY SE WITH A TARGET VOLUME OF EUR 125 MILLION
NOT FOR PUBLICATION OR DISTRIBUTION IN OR INTO THE UNITED STATES, AUSTRALIA, CANADA, CYPRUS, HONG KONG, ITALY, JAPAN, NEW ZEALAND, SOUTH AFRICA, THE UNITED KINGDOM OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION WOULD REQUIRE ANY FURTHER MEASURES FROM LR GLOBAL HOLDING GMBH, LR HEALTH & BEAUTY SE, PARETO SECURITIES AS, FRANKFURT BRANCH, ARCTIC SECURITIES AS OR ANY OTHER PARTY.
Disclosure of an inside information acc. to Art. 17 of the Regulation (EU) No. 596/2014 (Market Abuse Regulation – MAR)
LR GLOBAL HOLDING GMBH ANNOUNCES ITS INTENTION TO EXERCISE THE CALL-OPTION TO REDEEM ITS OUTSTANDING 2021/2025 BONDS SUBJECT TO A SENIOR SECURED BOND ISSUANCE BY LR HEALTH & BEAUTY SE WITH A TARGET VOLUME OF EUR 125 MILLION
Ahlen, 13 February 2024 – LR Global Holding GmbH (the “Company”) announces that the Company contemplates a refinancing of the Company’s outstanding EUR 125,000,000 senior secured 2021/2025 bonds with ISIN NO0010894850 (the “Existing Bonds”), subject to an issue of a new senior secured corporate bond under Swedish law (Nordic Bond) with a target volume of EUR 125,000,000 (the ”New Bonds”) by the Company’s parent company LR Health & Beauty SE.
LR Health & Beauty SE has mandated Pareto Securities AS, Frankfurt Branch and Arctic Securities AS as joint bookrunners to arrange credit investor meetings in connection with the issue of the New Bonds. A capital markets transaction may follow, subject to market conditions.
Subject to the successful issuance of the New Bonds and the receipt of the required net proceeds from such issuance, the Company intends to mainly use these proceeds to exercise its call-option and redeem in full the EUR 125,000,000 outstanding amount of its Existing Bonds. In accordance with the terms and conditions, the Existing Bonds due 2025 would be redeemed at a redemption price of 101.45 %, plus accrued and unpaid interest thereon up to, but excluding, the redemption date.
This announcement is not a redemption notice in accordance with the terms and conditions of the Existing Bonds, and such redemption notice will be given by the Company only upon a successful placement of the New Bonds on the basis of a book-building process.
IR contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Gebäude D
65195 Wiesbaden
Phone: +49(0)611 - 205855-23
Fax: +49(0)611 - 205855-66
E-mail: burbach@cometis.de
This information is information that LR Global Holding GmbH is obliged to make public pursuant to the EU Market Abuse Regulation (EU 596/2014). The information in this publication has been made public through the agency of the responsible person set out above for publication at the time stated by the Company's news distributor, EQS Group AG, at the time of publication.
Important Note
THE SECURITIES MENTIONED HEREIN HAVE NOT BEEN, AND WILL NOT BE, REGISTERED UNDER THE US SECURITIES ACT. THEY MAY NOT BE OFFERED OR SOLD IN THE UNITED STATES, EXCEPT PURSUANT TO AN EXEMPTION FROM THE REGISTRATION REQUIREMENTS OF THE U.S. SECURITIES ACT. NO PUBLIC OFFERING WILL BE MADE IN THE UNITED STATES AND THE INFORMATION CONTAINED HEREIN DOES NOT CONSTITUTE AN OFFER TO SELL NOR A SOLICITATION TO BUY OR SUBSCRIBE FOR SECURITIES OF LR GLOBAL HOLDING GMBH AND/OR LR HEALTH & BEAUTY SE AND NO EXCHANGE OFFER IS BEING MADE IN THE UNITED STATES, AUSTRALIA, CANADA, CYPRUS, HONG KONG, ITALY, JAPAN, NEW ZEALAND, SOUTH AFRICA, THE UNITED KINGDOM OR ANY OTHER JURISDICTION WHERE SUCH DISTRIBUTION/SUCH OFFER WOULD REQUIRE ANY FURTHER MEASURES FROM LR GLOBAL HOLDING GMBH, LR HEALTH & BEAUTY SE, PARETO SECURITIES AS, FRANKFURT BRANCH, ARCTIC SECURITIES AS OR ANY OTHER PARTY OR BE PROHIBITED BY APPLICABLE LAW.
Dr. Andreas Laabs becomes new chairman of the management board of the LR Group as successor for Andreas Friesch
Disclosure of an inside information acc. to Article 17 of the Regulation (EU) No 596/2014
Dr. Andreas Laabs becomes new chairman of the management board of the LR Group as successor for Andreas Friesch
Ahlen, 23 May 2022 – LR Global Holding GmbH ("Company") as the issuer of the bonds (WKN: A3H3FM / ISIN: NO0010894850) informs about the fact that Dr. Andeas Laabs, currently CFO and COO of the Company, will become the new chairman of the management board of LR Health & Beauty SE as well as CEO of the Company. The current chairman of the management board, Andreas Friesch, will for personal reasons by mutual agreement resign as chairman of the management board of LR Health& Beauty SE as well as managing director/CEO of the Company and will leave the LR Group on 27 May 2022.
IR Contact:
cometis AG
Thorben Burbach
Unter den Eichen 7 | Building D
65195 Wiesbaden
Tel.: +49 (0)611 - 205855-23
Fax: +49 (0)611 - 205855-66
E-Mail: burbach@cometis.de
Directors‘ Dealings
At the moment no news are available.